Verona Pharma plc's ensifentrine has a PDUFA date on June 26th for COPD treatment, with promising Phase 3 study results suggesting the drug will secure commercial approval.Potential competition from ...
Source LinkVerona Pharma plc's ensifentrine has a PDUFA date on June 26th for COPD treatment, with promising Phase 3 study results suggesting the drug will secure commercial approval.Potential competition from ...
Source Link
Comments